Security Snapshot

BioAtla, Inc. - Common Stocks, par value $0,0001 per share (BCAB) Institutional Ownership

CUSIP: 09077B104

13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026

13F reference period

Q2 2026

Institutions Reporting

1

Shares (Excl. Options)

108.13KFull value: 108,126 · shares · 30 Jun 2026

Price

$4.14

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stocks, par value $0,0001 per share
Symbol
BCAB on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
108,126
Latest holder snapshot 5 signals
Total 13F value
$447,645
Portfolio coverage rank
0%
Share change
-15,270,885
Value change
-$23,539,038
Number of holders
1
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
58,548,563
SEC-reported price per share
$4.14
Insider filing price
$4.14
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • BCAB - BioAtla, Inc. - Common Stocks, par value $0,0001 per share is tracked under CUSIP 09077B104.
  • 1 institution reported positions in Q2 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 34 to 1 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $2.47MFull value: $2,469,338 · USD · 31 Mar 2026
    to
    $447.65KFull value: $447,645 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 1 institution filings for Q2 2026.

Open SEC evidence

Security key

09077B104

13F reference period

Q2 2026

13F holders

1

13D/G owners

5

CIK / CUSIP context first

Open Q2 2026 holders BCAB full holder history BioAtla, Inc. SEC filings BioAtla, Inc. company facts BioAtla, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
BCAB
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HIGHBRIDGE CAPITAL MANAGEMENT LLC 7.7% -22% $2,129,415 -$1,104,235 4,839,579 -34% Highbridge Capital Management, LLC 31 Mar 2025
ACORN BIOVENTURES, L.P. 8.3% $2,127,449 4,835,111 Anders Hove 15 May 2025
SHORT JAY M PHD 6.6% $1,700,884 3,865,646 Jay M. Short 31 Dec 2024
OPOKA INVESTMENT FUND Co 4.8% -22% $1,933,227 -$507,296 2,810,331 -21% OPOKA INVESTMENT FUND Co 09 Jul 2025
MILLENNIUM MANAGEMENT LLC 1.9% $482,067 1,095,606 Millennium Management LLC 31 Dec 2024
As of 30 Jun 2026, 1 institutional investors reported holding
108.13KFull value: 108,126 · shares · 30 Jun 2026
shares of BioAtla, Inc. - Common Stocks, par value $0,0001 per share (BCAB). This represents 0.18% of the company’s total
58.55MFull value: 58,548,563 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
23
Headline period
Q2 2026
Rows shown
1-23 of 23
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 108,126 $447,645 -$23,539,038 $4.14 1
2026 Q1 15,379,483 $2,469,338 -$141,307 $0.16 34
2025 Q4 13,178,637 $7,494,979 -$262,374 $0.57 40
2025 Q3 13,349,032 $9,190,012 +$218,760 $0.69 43
2025 Q2 13,168,921 $5,214,805 -$178,456 $0.40 39
2025 Q1 13,676,589 $4,757,169 -$6,041,757 $0.35 40
2024 Q4 24,014,047 $14,192,960 -$3,984,785 $0.59 67
2024 Q3 17,681,418 $31,044,305 -$6,375,131 $1.76 63
2024 Q2 22,134,924 $30,397,774 -$9,819,957 $1.37 78
2024 Q1 25,353,603 $87,226,850 -$3,078,466 $3.44 83
2023 Q4 27,002,533 $66,550,242 -$6,102,978 $2.46 79
2023 Q3 29,893,256 $50,818,372 -$3,978,003 $1.70 80
2023 Q2 32,003,208 $96,009,836 -$889,082 $3.00 86
2023 Q1 32,818,307 $87,622,240 -$35,920,780 $2.68 79
2022 Q4 33,849,374 $279,248,047 +$75,723,026 $8.25 88
2022 Q3 24,872,441 $191,538,348 +$24,104,114 $7.70 66
2022 Q2 23,517,118 $67,049,000 -$8,813,651 $2.85 71
2022 Q1 25,528,713 $127,715,000 -$39,588,884 $5.00 91
2021 Q4 26,409,935 $518,424,807 +$9,459,769 $19.63 79
2021 Q3 25,357,996 $746,373,968 +$120,415,617 $29.44 83
2021 Q2 21,165,507 $896,994,925 +$89,307,130 $42.38 73
2021 Q1 19,002,884 $964,589,936 +$187,867,257 $50.84 62
2020 Q4 15,664,281 $530,219,000 +$530,219,000 $34.01 53
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .